Agenus faces uphill battle as FDA advice on cancer drug combo sparks stock selloff
2024-07-18
Agenus shares plunged over 54% on Thursday after the company revealed that the FDA "discouraged" its pursuit of accelerated approval for an immunotherapy combination in microsatellite stable colorectal cancer (MSS CRC), the most prevalent form of the disease. The setback affects the company's dual approach combining botensilimab, an Fc-enhanced anti-CTLA-4 antibody, with the PD-1 inhibitorPD-1 inhibitor balstilimab for patients with relapsed or refractory disease.
The negative market reaction came as Agenus revealed outcomes of its end-of-Phase II meeting with the FDA, where the agency advised against submitting recent trial results in a bid to secure a speedy approval for the regimen. The FDA's stance was based on the view that the objective response rates (ORRs) observed may not necessarily translate to a survival benefit.
Topline interim data from the ongoing Phase II trial showed trends consistent with earlier Phase I results, according to the company. In the cohort receiving the agreed-upon Phase III dose (BOT 75 mg/BAL 240 mg), Agenus said the ORR was 19.4% after a median 9.5 months of follow-up, with a six-month survival rate 90% and data continuing to mature. At the increased BOT dose of 150 mg, the combination was associated with an 8.2% ORR.
Results of a 77-patient Phase I study reported earlier this year, had shown a 23% ORR with the regimen after a median follow-up of 13.6 months. The estimated median overall survival was 21.2 months. Like the Phase II trial, the earlier study also included refractory MSS CRC patients with no active liver metastases.
Open to partnerships
Steven O'Day, the company's chief medical officer, indicated Thursday that Agenus was still committed to the programme despite the regulatory hurdle.
"Based on the high level of enthusiasm from significant numbers of global clinical experts and the promising clinical activity we have seen in the Phase I and II studies, our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering," O'Day stated, adding "this includes exploring opportunities to partner in the US to accomplish a successful Phase III trial."
In the meantime, Agenus says it is ploughing ahead with efforts to bring BOT/BAL to patients in Europe, where discussions to explore registration paths are scheduled for later this summer.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。